Comparative Pharmacology
Head-to-head clinical analysis: PALIPERIDONE PALMITATE versus RISVAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PALIPERIDONE PALMITATE versus RISVAN.
PALIPERIDONE PALMITATE vs RISVAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paliperidone is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors. It also blocks alpha-2 adrenergic and H1 histaminergic receptors.
Risperidone is an atypical antipsychotic that acts as a serotonin 5-HT2A and dopamine D2 receptor antagonist. It also binds to alpha1-adrenergic and H1 histaminergic receptors.
Paliperidone palmitate is administered intramuscularly. Initial dose: 150 mg eq. on day 1 and 100 mg eq. on day 8, both in the deltoid muscle. Maintenance dose: 75 mg eq. monthly (range 25–150 mg eq.) administered in the deltoid or gluteal muscle.
70 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life: 25-49 days (mean ~30 days) for IM injection; allows monthly dosing
Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 20-30 hours in hepatic impairment (Child-Pugh B/C).
Renal: 80% as unchanged drug and metabolites; fecal: 11%
Renal: 30% unchanged; Fecal: 65% (biliary excretion of metabolites); 5% other.
Category A/B
Category C
Atypical Antipsychotic
Atypical Antipsychotic